Regulus Therapeutics Stock (NASDAQ: RGLS)

Regulus Therapeutics Stock (NASDAQ:RGLS), Trade Ideas

Regulus Therapeutics

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Regulus Therapeutics Inc

REGULUS RES INC by Regulus Resources, Inc.

Regulus Resources Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and maintains $9 price target.

News

Price Target

Reiteration

Analyst Ratings

RGLS

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is unchanged from the same period last year.

Earnings

Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and lowers the price target from $12 to $11.

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11

Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Outperform rating and announces Price Target of $6.

Initiation

Leerink Partners Initiates Coverage On Regulus Therapeutics with Outperform Rating, Announces Price Target of $6

WIIM

Regulus Therapeutics shares are trading higher after Wells Fargo maintained an Equal-Weight rating on the stock and raised its price target from $2 to $3.

Wells Fargo analyst Jim Birchenough maintains Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Equal-Weight and raises the price target from $2 to $3.

Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock increased by 94.9% to $2.69 during Tuesday's regular session. The company's market cap stands at $54.3 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares increased by 66.42% to $0.35. The market value of their outstanding shares is at $63.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 29.33% to $2.42. The company's market cap stands at $2.9 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock moved upwards by 21.55% to $0.41. The market value of their outstanding shares is at $2.7 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock increased by 18.89% to $0.34. The market value of their outstanding shares is at $15.6 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) stock increased by 17.96% to $1.05. The market value of their outstanding shares is at $41.2 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) stock declined by 30.5% to $4.34 during Tuesday's regular session. The company's market cap stands at $53.7 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares declined by 28.56% to $0.48. The market value of their outstanding shares is at $43.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 24.86% to $1.33. The company's market cap stands at $17.8 million. </li>
<li>Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) shares decreased by 24.38% to $5.46. The market value of their outstanding shares is at $482.8 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock fell 23.4% to $0.87. The company's market cap stands at $43.6 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock declined by 20.31% to $2.04. The market value of their outstanding shares is at $44.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BGXX

CRBU

IONM

LEXX

NKGN

NRXP

RNLX

TCON

VIRX

WORX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Trading Ideas

Regulus Therapeutics Shares Resume Trade

Regulus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 116.7%

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's market cap stands at $51.5 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock increased by 73.02% to $0.59. The market value of their outstanding shares is at $3.9 million. </li>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) shares increased by 24.89% to $8.58. The market value of their outstanding shares is at $262.6 million. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares increased by 16.0% to $6.16. The market value of their outstanding shares is at $387.8 million. The company's, Q4 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock increased by 14.79% to $7.45. The company's market cap stands at $199.0 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) stock moved upwards by 14.37% to $0.79. The company's market cap stands at $8.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares fell 27.2% to $0.83 during Tuesday's pre-market session. The market value of their outstanding shares is at $41.4 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock declined by 17.63% to $2.07. The company's market cap stands at $138.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 17.52% to $1.46. The market value of their outstanding shares is at $19.5 million. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) stock fell 16.46% to $20.16. The market value of their outstanding shares is at $3.3 billion. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock declined by 16.3% to $0.56. The market value of their outstanding shares is at $51.3 million. </li>
<li>Finch Therapeutics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNCH#NASDAQ">FNCH</a>) shares fell 13.7% to $2.95. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

CTMX

FNCH

GNLX

TELO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

ORCL: 14% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37611320">Oracle shares are trading higher after the company reported Q3 financial results.</a>
RGLS: 103% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37612875">Regulus Therapeutics shares are trading higher after the company announced topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The company announced an oversubscribed $100 million private placement of equity.</a>
ONON: -18% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37611320">On Holding shares are trading lower after the company reported worse-than-expected Q4 financial results.</a>
&nbsp;

ONON

ORCL

Market-Moving News for March 12th

Tuesday,&nbsp;Regulus Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) released topline results from the second cohort of patients in its Phase 1b multiple-ascending dose (MAD) study of RGLS8429 for Autosomal Dominant&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37610949/regulus-therapeutics-announces-positive-topline-data-from-the-second-cohort-of-patients-in-its-pha" rel="noreferrer noopener">Polycystic Kidney Disease (ADPKD)</a>.
The study evaluates RGLS8429 treatment across three different weight-based dose levels, including measuring changes in urinary polycystins 1 and 2 (PC1 and PC2), height-adjusted total kidney volume (htTKV), cyst architecture, and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/09/34767944/regulus-therapeutics-releases-early-data-from-of-investigational-for-rare-type-of-kidney-disease" rel="noreferrer noopener">overall kidney function</a>.&nbsp;
PC1 and PC2 are the protein products of the PKD1 and PKD2 genes and have been shown to correlate with disease severity inversely.&nbsp;
RGLS8429 was well tolerated, with no safety findings of concern.
Clear evidence of a mechanistic dose response at a 2mg/kg dose level based on urinary PC1 and PC2 polycystin levels was observed.
Urinary measurements of PC1 and PC2 demonstrated greater biological activity of RGLS8429 at 2mg/kg compared to 1mg/kg and placebo, which was most evident after three months of dosing.
Exploratory results of imaging-based biomarkers were encouraging, with three patients with the highest increases in PC1 and PC2 having reductions in htTKV &gt;4%, with corresponding reductions in total kidney cyst volume (TKCV).
The third cohort is being dosed at 3mg/kg of RGLS8429 or placebo every other week for three months. Data readout is anticipated in mid-2024.
The company recently added a fourth cohort for an open-label fixed dose of 300mg of RGLS8429 dosed every other week for three months. Screening is expected to start in the second quarter of 2024.
Concurrently, Regulus Therapeutics announced an oversubscribed $100 million&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37610996/regulus-therapeutics-announces-oversubscribed-100-million-private-placement-of-equity" rel="noreferrer noopener">equity private placement</a>.&nbsp;
Under the securities purchase agreement, the investors have agreed to purchase shares at $1.60 per share.&nbsp;
Certain investors have also agreed to purchase, in lieu of common shares, shares of newly designated, non-voting Class A-6 convertible preferred stock at a purchase price of $160.00 per share.&nbsp;
Price Action: RGLS shares are up 52% at $2.11 during the premarket session on the last check Tuesday.
Photo: Darko Stojanovic from Pixabay

Biotech

Equities

Health Care

Financing

Offerings

General

Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?

Regulus Therapeutics shares are trading higher after the company announced topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The company announced an oversubscribed $100 million private placement of equity.

Regulus Therapeutics Announces Oversubscribed $100M Private Placement Of Equity; Investors Will Purchase The Shares At $1.60/Share

<ul>
<li>Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses</li>
<li>Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2</li>
<li>Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024</li>
</ul>

Regulus Therapeutics Released Topline Data From The Second Cohort Of Patients In Its Phase 1b Multiple-Ascending Dose Trial Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Completes Enrollment In Third Cohort Of Patients In Phase 1B MAD Study Of RGLS8429 For Treatment Of ADPKD

Regulus Therapeutics Announced The Dosing Of The First Patient In The Third Cohort Of The Phase 1B MAD Study Of RGSL8429 For Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Will Advance To Third Cohort Of Patients In The Phase 1B Mad Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease; Patients In The Third Cohort Will Receive 3 mg/kg Of RGLS8429 Or Placebo Every Other Week For Three Month

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock increased by 12.4% to $1.45 during Thursday's after-market session. The company's market cap stands at $28.2 million. </li>
<li>SeqLL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQL#NASDAQ">SQL</a>) shares moved upwards by 10.34% to $15.79. The company's market cap stands at $6.0 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares moved upwards by 9.43% to $1.16. The market value of their outstanding shares is at $10.1 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares increased by 9.05% to $2.65. The market value of their outstanding shares is at $5.7 million. </li>
<li>Blue Water Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWV#NASDAQ">BWV</a>) shares rose 8.67% to $0.61. Trading volume for this security closed at 129.4K, accounting for 130.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.7 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 7.01% to $0.14. At the close, China Pharma Holding's trading volume reached 65.8K shares. This is 7.2% of its average volume over the last 100 days. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baudax Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BXRX#NASDAQ">BXRX</a>) shares decreased by 10.1% to $0.31 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. </li>
<li>Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) stock declined by 6.49% to $0.43. The market value of their outstanding shares is at $13.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock decreased by 6.45% to $0.65. Today's trading volume for this security ended up closing at 583.3K shares, which is 103.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock fell 5.33% to $0.37. The market value of their outstanding shares is at $19.9 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) stock declined by 4.63% to $2.89. The market value of their outstanding shares is at $540.3 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock decreased by 4.57% to $0.21. The market value of their outstanding shares is at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

BXRX

CPHI

ENVB

RNAZ

SRZN

TSHA

12 Health Care Stocks Moving In Thursday's After-Market Session

Regulus Therapeutics Inc (RGLS) is near the top in its industry group according to InvestorsObserver. RGLS gets an overall rating of 84. That means it scores higher than 84 percent of stocks. Regulus Therapeutics Inc gets a 96 rank in the Biotechnology industry. Biotechnology is number 21 out of 148 industries. RGLS has an

Regulus Therapeutics Inc (RGLS) is higher by 4.92% in a Week, Should You Sell?

Regulus Therapeutics GAAP EPS of -$0.40 in-line

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Regulus Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgls-stock-quote/">RGLS</a>) just reported results for the fourth quarter of 2023.<ul><li>Regulus Therapeutics reported earnings per share of -40 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/rgls-stock-earnings-regulus-therapeutics-for-q4-of-2023/">RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Regulus (RGLS – Research Report) today and set a price target of $3.00. Yanan Zhu has giv...

Maintaining Hold on Regulus: A Balanced View of Financial Stability and Awaited Clinical Milestones

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on RGLS stock, giving a Buy rating on March 20. Ram Selvaraju has given h...

Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regulus (RGLS – Research Report), Axsome Therapeutics (AXSM – Res...

Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regulus (RGLS – Research Report), Hims & Hers Heal...

Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Hims & Hers Health (HIMS) and Olink Holding (OLK)

Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Regulus (RGLS – Research Report), with a price target of $11.00. Whitney Ijem ...

Buy Rating on Regulus's RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs

Regulus files to sell 62.5M shares of common stock for holders

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

AXSM

HIMS

Press Releases

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Small Cap

Opinion

Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew?

Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates